Nuvera Biosciences: Breast Cancer Genomic Test Shown to Predict Patient Survival Following Adjuvant Chemotherapy
Published: Jun 03, 2011
Nuvera Biosciences, a molecular diagnostics company that develops gene-based diagnostic assays for personalized medicine in cancer, announced the results of a blinded validation study on its breast cancer assay for taxane chemotherapy response. The study is being presented at the ASCO Annual Meeting on June 4 in Chicago (McCormick Place Hall B1, 2-6pm; J Clin Oncol 29: 2011; suppl; abstr 1030). The study authors include investigators from University of Texas M.D. Anderson Cancer Center; Institut Gustave-Roussy, France ; Medical University of Graz, Austria; Institute of Oncology, University of Ljubljana, Slovenia; and Georgetown Lombardi Comprehensive Cancer Center.